Forgot your password?
Forgot your username?
JOIN THE LPMA
FIND A PSYCHIATRIST
FOR THE PUBLIC
News, Information & Links
Continuing Medical Education
LPMA News & Updates
APA News & Updates
Please mark your calendars!
2014 Fall Meeting 04
2014 Fall Meeting 03
2014 Fall Meeting 02
2014 Fall Meeting 01
Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks
Find a Psychiatrist
Resources for the Public
Calendar of Events
A.G. Schneiderman Announces Settlement With Emblem Health For Wrongly Denying Mental Health And Substance Abuse Treatment For Thousands Of New York Members |
Click here to read the article
| The APA is now accepting abstract submissions for its
168th Annual Meeting to be held in Toronto, Ontario, Canada. May 16-21, 2015
. The theme of the meeting is
Psychiatry: Integrating Body and Mind, Heart and Soul.
The submission deadline is
Tuesday, September 9, 2014.
To submit an abstract, review the types of abstracts to be submitted, or learn more about the 2015 Annual Meeting please click
Psychiatric News Alert
The Voice of the
American Psychiatric Association
and the Psychiatric Community
FDA Approves New Abuse-Deterrent Labeling for Opioid Analgesic
The U.S. Food and Drug Administration (FDA) approved new labeling for Embeda, an opioid analgesic to treat severe pain. The new labeling includes a statement indicating that Embeda has properties that are expected to reduce oral abuse of the drug when the product is crushed.
Embeda becomes the third opioid analgesic to be approved with an abuse-deterrent label, in line with the FDA’s 2013 draft guidance,
Abuse-Deterrent Opioids – Evaluation and Labeling.
Embeda, which is manufactured by Pfizer, is a combination of morphine sulfate and naltrexone hydrochloride. These agents have competing actions on the opioid receptor; when capsules are swallowed intact, only the morphine is released, producing pain relief but creating the risk of abuse and addiction. When crushed, the naltrexone is also activated, blocking some of the euphoric effects of morphine. This reduces the risk of abuse, though not completely preventing it, for people who improperly use the drug such as by inhaling it.
Though the new labeling is approved, the FDA will require additional postmarketing studies of Embeda to further assess the effects of the abuse-deterrent features on the risk—and consequences—of abuse, particularly in regard to intravenous use. The agency is also holding a
public meeting on October 30-31 in Silver Spring, Md.
, to further discuss the development of abuse-deterrent opioids.
To read about initiatives and recommendations for reducing opioid abuse, see...
MARK YOUR CALENDARS
Louisiana Psychiatric Medical Association &
Mississippi Psychiatric Association in Collaboration with the Louisiana & Mississippi Councils for Child & Adolescent Psychiatry
Join to Present their
February 27-28, 2015
Mississippi Gulf Coast
Please mark your calendars and stay tuned for more details.
LPMA • 9655 Perkins Rd. #C-152 • Baton Rouge, LA 70810 • PH: 225-761-3718 • FAX: 228-215-1256 •
Web Design by
Bruner and Company